UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Takes Position in Astrana Health, Inc. (NASDAQ:ASTH)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 90,520 shares of the company's stock, valued at approximately $5,245,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.18% of Astrana Health as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC purchased a new position in shares of Astrana Health in the 3rd quarter valued at about $34,000. Nisa Investment Advisors LLC acquired a new stake in Astrana Health in the third quarter valued at approximately $35,000. KBC Group NV acquired a new stake in Astrana Health in the third quarter valued at approximately $70,000. Quest Partners LLC purchased a new position in Astrana Health in the third quarter worth approximately $133,000. Finally, Central Pacific Bank Trust Division acquired a new position in Astrana Health during the 3rd quarter worth approximately $160,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Astrana Health Stock Performance

Shares of NASDAQ ASTH traded down $0.76 during trading hours on Thursday, reaching $37.74. The stock had a trading volume of 214,887 shares, compared to its average volume of 212,557. The firm has a 50-day moving average of $50.37 and a 200-day moving average of $48.11. The firm has a market cap of $2.12 billion, a price-to-earnings ratio of 29.42, a PEG ratio of 1.94 and a beta of 1.13. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health, Inc. has a fifty-two week low of $33.24 and a fifty-two week high of $63.20.

Astrana Health (NASDAQ:ASTH - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, meeting analysts' consensus estimates of $0.33. The company had revenue of $478.71 million during the quarter, compared to analysts' expectations of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same quarter in the previous year, the business earned $0.47 earnings per share. Equities research analysts predict that Astrana Health, Inc. will post 1.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ASTH. TD Cowen began coverage on shares of Astrana Health in a research report on Monday, October 14th. They set a "buy" rating and a $66.00 price objective for the company. Robert W. Baird upped their price objective on Astrana Health from $67.00 to $86.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. BTIG Research raised their target price on Astrana Health from $60.00 to $70.00 and gave the stock a "buy" rating in a research report on Thursday, October 3rd. Finally, KeyCorp assumed coverage on Astrana Health in a report on Friday, October 11th. They issued a "sector weight" rating for the company. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Astrana Health presently has a consensus rating of "Buy" and a consensus target price of $65.17.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.